TY  - JOUR
AU  - Köbel, Martin
AU  - Yang, Rui Zhe
AU  - Kang, Eun Young
AU  - Al-Shamma, Zainab
AU  - Cook, Linda S
AU  - Kinloch, Mary
AU  - Carey, Mark S
AU  - Hopkins, Laura
AU  - Nelson, Gregg S
AU  - McManus, Kirk J
AU  - Vizeacoumar, Frederick S
AU  - Vizeacoumar, Franco J
AU  - Freywald, Andrew
AU  - Fu, YangXin
AU  - Reuss, David E
AU  - Lee, Cheng-Han
TI  - Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.
JO  - Gynecologic oncology
VL  - 178
SN  - 0090-8258
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2023-02050
SP  - 80 - 88
PY  - 2023
AB  - Inhibition of the MAPK pathway by MEK inhibitors (MEKi) is currently a therapeutic standard in several cancer types, including ovarian low-grade serous carcinoma (LGSC). A common MAPK pathway alteration in tubo-ovarian high-grade serous carcinoma (HGSC) is the genomic inactivation of neurofibromin 1 (NF1). The primary objectives of our study were to survey the prevalence of NF1 inactivation in the principal ovarian carcinoma histotype as well as to evaluate its associations with clinico-pathological parameters and key biomarkers including BRCA1/2 status in HGSC.A recently commercialized NF1 antibody (clone NFC) was orthogonally validated on an automated immunohistochemistry (IHC) platform and IHC was performed on tissue microarrays containing 2140 ovarian carcinoma cases. Expression was interpreted as loss/inactivated (complete or subclonal) versus normal/retained.Loss of NF1 expression was detected in 250/1429 (17.4
KW  - High-grade serous carcinoma (Other)
KW  - NF1 (Other)
KW  - Ovarian cancer (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37820398
DO  - DOI:10.1016/j.ygyno.2023.09.016
UR  - https://inrepo02.dkfz.de/record/284647
ER  -